Literature DB >> 10860780

The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1).

H T Orr1.   

Abstract

Polyglutamine neurodegenerative disorders are characterized by the expansion of a glutamine tract within the mutant disease-causing protein. Expression of the mutant protein induces a progressive loss of neuronal function and the subsequent neurodegeneration of a set of neurons characteristic to each disease. Spinocerebellar ataxia type 1 (SCA1) is one polyglutamine disease where various experimental model systems, in particular transgenic mice, have been utilized to dissect the molecular and cellular events important for disease. This review summarizes these findings and places them in a context of potential future research directions. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860780     DOI: 10.1006/nbdi.2000.0305

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  5 in total

1.  Diagnosis of five spinocerebellar ataxia disorders by multiplex amplification and capillary electrophoresis.

Authors:  Michael O Dorschner; Deborah Barden; Karen Stephens
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

Review 2.  Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics.

Authors:  Nathaniel Robb Whaley; Shinsuke Fujioka; Zbigniew K Wszolek
Journal:  Orphanet J Rare Dis       Date:  2011-05-28       Impact factor: 4.123

Review 3.  Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools.

Authors:  Marianna Karwacka; Marta Olejniczak
Journal:  Cells       Date:  2022-02-02       Impact factor: 6.600

4.  Analysis of autosomal dominant spinocerebellar ataxia type 1 in an extended family of central India.

Authors:  Shashikant Sharma; Tekcham Dinesh Singh; Satish S Poojary; Manoj Singh Rohilla; Ajaypal Singh; Kishore B Lowalekar; Pramod Kumar Tiwari
Journal:  Indian J Hum Genet       Date:  2012-09

5.  Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity.

Authors:  Maria Tsirigotis; R Mitchell Baldwin; Matthew Y Tang; Ian A J Lorimer; Douglas A Gray
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.